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Abstract
Background: Psoralea Fructus (PF), the dried and ripe fruit of Psoralea corylifolia exhibits an anti-cancer activity.
However, the molecular mechanisms by which PF inhibits the proliferation of cancer cells have not been elucidated
in detail. Cyclin D1 and CDK4 are important regulatory proteins in cell growth and are overexpressed in many
cancer cells. In this study, we investigated the molecular mechanism of PF on the downregulation of cyclin D1 and
CDK4 level.
Methods: Cell growth was evaluated by MTT assay. The effect of PF on cyclin D1 and CDK4 expression was
evaluated by Western blot or RT-PCR.
Results: PF suppressed the proliferation of human colorectal cancer cell lines such as HCT116 (IC50: 45.3 ± 1.2 μg/
ml), SW480 (IC50: 37.9 ± 1.6 μg/ml), LoVo (IC50: 23.3 ± 1.9 μg/ml μg/ml) HT-29 (IC50 value: 40.7 ± 1.5 μg/ml). PF
induced decrease in the protein expression of cyclin D1 and CDK4. However, the mRNA expression of cyclin D1
and CDK4 did not be changed by PF; rather it suppressed the expression of cyclin D1 and CDK4 via the
proteasomal degradation. In cyclin D1 degradation, we found that T286 of cyclin D1 play a pivotal role in PF-
mediated cyclin D1 degradation. Subsequent experiments with several kinase inhibitors suggest that PF-mediated
degradation of cyclin D1 and CDK4 is dependent on ERK1/2 and/or GSK3β.
Conclusions: Our results suggest that PF has potential to be a candidate for the development of chemoprevention
or therapeutic agents for human colorectal cancer.
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Background
Medicinal herbals have gained increasing attention for
their effectiveness and relatively minor side effects [1].
Psoralea Fructus (PF), the dried and ripe fruit of Psora-
lea corylifolia known as “Bo-Gol-Zhee” in Korea has
been used as traditional medicine in Asian [2]. PF has
been demonstrated to exert unique effectiveness against
infectious disease, inflammatory disorder, tumor and
depression [3–5]. Many active components have been
identified in PF, and most of them belong to coumarins
(psoralen, isopsoralen, and psoralidin) and flavonoids
(bavachin, isobavachalcone and neobavaisoflavone) [6].
These compounds show anti-oxidative, anti-tumor, anti-
bacterial, and protective effects on cutaneous com-
plaints, impotence, and hepatic injury [7]. In anticancer
activity, PF has been reported to induce the cell growth
arrest and apoptosis in human oral carcinoma lines and
erythroleukemia cells [5]. However, the potential mech-
anism by which PF induces the cell growth arrest has
remained unknown.
Cyclin D1 as an oncogenic protein facilitates cell cycle
progression via several transcriptional factor by an active
complex with cyclin-dependent kinase 4/6 (CDK4/6) [8].
Overexpression of cyclin D1 found in various cancer
cells is associated with the poor prognosis of tumor and
metastasis [9]. Especially, cyclin D1 overexpression has
been overexpressed in 68.3 % of human colorectal can-
cer case and deregulation of cyclin D1 has been associ-
ated with colorectal tumorigenesis [10, 11]. Thus, it has
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been accepted that cyclin D1 has been an attractive che-
mopreventive and therapeutic target for anti-cancer devel-
opment [12]. In addition, mutation or amplification of
CDK4 is associated with the transition from G1 to S phase
and ultimately induces cancer cell growth [13]. CDK4 has
been reported to be overexpressed in breast, head and
neck and lung cancer cells [13]. CDK4 overexpression has
been observed in 87 % of human colorectal cancer [14].
Thus, the CDK4 inhibition offers an attractive therapeutic
strategy for anti-cancer development due to the import-
ance of CDK4 activity in regulating cell proliferation [13].
In the current study, we evaluated the effect of the
ethanol extracts from PF on cyclin D1 and CDK4
suppression in the colorectal cancer cells. We found
that the ethanol extracts from Psoralea fructus down-




Cell culture media, Dulbecco’s Modified Eagle
medium (DMEM)/F-12 1:1 Modified medium
(DMEM/F-12) was purchased from Lonza (Walkers-
ville, MD, USA). PD98059, SB203580, SP600125, LiCl,
MG132 and 3-(4,5-dimethylthizaol-2-yl)-2,5-diphenyl
tetrazolium bromide (MTT) were purchased from
Sigma Aldrich (St. Louis, MO, USA). Antibodies
against cyclin D1, phospho-cyclin D1 (Thr286),
HA-tag, CDK4, p-ERK1/2, total-ERK1/2, p-GSK3β,
total-GSK3β and β-actin were purchased from Cell
Signaling (Bervely, MA, USA). All chemicals were
purchased from Fisher Scientific, unless otherwise
specified.
Sample preparation
Psoralea Fructus (PF), the dried and ripe fruit of Psoralea
corylifolia were kindly provided by the Bonghwa Alpine
Medicinal Plant Experiment Station, Korea. Psoralea Fruc-
tus (voucher number: Koo001(ANH)) was formally identi-
fied by Jin Suk Koo as the professor of Andong National
University, Korea. Two hundred gram of PF was extracted
with l L of 70 % ethanol with shaking for 48 h. After 48 h,
the ethanol-soluble fraction was filtered and concentrated
to approximately 300 ml volume using a vacuum evapor-
ator and then freeze-dried. The ethanol extracts from PF
was kept in a refrigerator until use.
Cell culture and treatment
Human colorectal cancer cell lines such as HCT116,
SW480, LoVo and HT-29 were purchased from Korean
Cell Line Bank (Seoul, Korea) and grown in DMEM/
F-12 supplemented with 10 % fatal bovine serum (FBS),
100 U/ml penicillin and 100 μg/ml streptomycin. The
cells were maintained at 37 oC under a humidified
atmosphere of 5 % CO2. The ethanol extracts from Psor-
alea Fructus (PF) was dissolved in dimethyl sulfoxide
(DMSO) and treated to cells. DMSO was used as a ve-
hicle and the final DMSO concentration did not exceed
0.1 % (v/v).
Cell proliferation assay
Cell growth was measured using MTT assay system.
Briefly, cells were plated onto 96-well plated and grown
overnight. The cells were treated with 0, 25, 50 and
100 μg/ml of PF for 24 h. Then, the cells were incubated
with 50 μl of MTT solution (1 mg/ml) for an additional
2 h. The resulting crystals were dissolved in DMSO. The
formation of formazan was measured by reading absorb-
ance at a wavelength of 570 nm.
SDS-PAGE and Western blot
After PF treatment, cells were washed with 1 × phosphate-
buffered saline (PBS), and lysed in radioimmunoprecipita-
tion assay (RIPA) buffer (Boston Bio Products, Ashland,
MA, USA) supplemented with protease inhibitor cocktail
(Sigma-Aldrich) and phosphatase inhibitor cocktail (Sigma-
Aldrich), and centrifuged at 15,000 × g for 10 min at 4 °C.
Protein concentration was determined by the bicinchoninic
acid (BCA) protein assay (Pierce, Rockford, IL, USA). The
proteins were separated on SDS-PAGE and transferred to
PVDF membrane (Bio-Rad Laboratories, Inc., Hercules, CA,
USA). The membranes were blocked for non-specific bind-
ing with 5 % non-fat dry milk in Tris-buffered saline con-
taining 0.05 % Tween 20 (TBS-T) for 1 h at room
temperature and then incubated with specific primary anti-
bodies in 5 % non-fat dry milk at 4 °C overnight. After three
washes with TBS-T, the blots were incubated with horse
radish peroxidase (HRP)-conjugated immunoglobulin G
(IgG) for 1 h at room temperature and chemiluminescence
was detected with ECL Western blotting substrate (Amer-
sham Biosciences, Piscataway, NJ, USA) and visualized in
Polaroid film.
Reverse transcriptase-polymerase chain reaction (RT-PCR)
After PF treatment, total RNA was prepared using a
RNeasy Mini Kit (Qiagen, Valencia, CA, USA) and total
RNA (1 μg) was reverse-transcribed using a Verso cDNA
Kit (Thermo Scientific, Pittsburgh, PA, USA) according
to the manufacturer’s protocol for cDNA synthesis. PCR
was carried out using PCR Master Mix Kit (Promega,
Madison, WI, USA) with human primers for cyclin D1,
CDK4 and GAPDH as followed : cyclin D1: forward 5′-
aactacctggaccgcttcct-3′ and reverse 5′-ccacttgagcttgttca
cca-3′, CDK4: forward 5′-atggctgccactcgatatgaaccc-3′
and reverse 5′-gtaccagagcgtaaccaccacagg-3′, GAPDH:
forward 5′-acccagaagactgtggatgg-3′ and reverse 5′-ttctag
acggcaggtcaggt-3′.
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Expression vectors
Wild type HA-tagged cyclin D1 and point mutation
of T286A of HA-tagged cyclin D1 were provided
from Addgene (Cambridge, MA, USA). Transient
transfection of the vectors was performed using the
PolyJet DNA transfection reagent (SignaGen Labora-
tories, Ijamsville, MD, USA) according to the manu-
facturers’ instruction.
Statistical analysis
All the data are shown as mean ± SEM (standard
error of mean). Statistical analysis was performed with
one-way ANOVA followed by Dunnett’s test. Differ-
ences with *P < 0.05 were considered statistically
significant.
Results
PF inhibits cell proliferation, and decreases the
expression of cyclin D1 and CDK4
To evaluate whether PF affects the proliferation of hu-
man colorectal cancer cells, MTT assay was performed.
As shown in Fig. 1, PF treatment for 24 h suppressed
the cell growth of HCT116 and SW480 cells by 38 %
and 47 % at 25 μg/ml, 54 % and 61 % at 50 μg/ml, and
63 % and 70 % at 100 μg/ml, respectively. In addition,
the proliferation of HT-29 and LoVo cells was inhibited
by PF treatment at 42 % and 56 % at 25 μg/ml, 69 % and
68 % at 50 μg/ml, and 79 % and 74 % at 100 μg/ml, re-
spectively. Since cell growth inhibition is related to cell
cycle arrest, we investigated the expression of cyclin D1
and CDK4 involved in cell cycle progression. The cells
were treated with 12.5 and 25 μg/ml for 24 h and
Fig. 1 The effect on PF on the cell proliferation in human colorectal cancer cells. The cells were plated overnight and then treated with PF for
24 h. Cell proliferation was measured using MTT assay as described in Materials and methods. *P < 0.05 compared to cell without PF treatment
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Western blot was performed. As shown in Fig. 2a-d, the
proteins of cyclin D1 and CDK4 were down-regulated by
PF treatment. In time-course experiment (Fig. 2e), the
protein expression of cyclin D1 started to be decreased at
1 h after PF treatment, while CDK4 expression was sup-
pressed at 10 h after PF treatment.
Effect of PF on the transcriptional and post-translational
regulation of cyclin D1 and CDK4
To elucidate the potential mechanism by which PF
down-regulates the protein level of cyclin D1 and
CDK4, the cells were treated with PF, and then
mRNA levels of cyclin D1 and CDK4 were evaluated
using RT-PCR. As shown in Fig. 3a-d, the mRNA
levels of cyclin D1 and CDK4 were not significantly
changed in the presence of PF. This result indicates
that PF may regulate the protein level of cyclin D1
and CDK4 through proteasomal-dependent degrad-
ation. To investigate whether PF affects the modifica-
tion of cyclin D1 and CDK4 protein, HCT116 cells
were pretreated with MG132 for 2 h, and then co-
treated with PF for 3 h for cyclin D1 or 10 h for
CDK4. As shown in Fig. 3e, the degradation of cyclin
D1 and CDK4 protein was restored in presence of
the proteasomal inhibitor, MG132, which suggests
that PF down-regulates cyclin D1 and CDK4 protein
at the post-translational level via the proteasomal
pathway.
Cyclin D1 degradation by PF is dependent on threonine-
286 (Thr-286) phosphorylation
Threonine-286 (Thr-286) phosphorylation of cyclin D
and subsequent ubiquitination pathway has been re-
ported to be the main cyclin D1 degradation pathway
[15]. To investigate whether Thr-286 phosphorylation
is critical in PF-mediated cyclin D1 degradation,
HCT116 cells were transfected with HA-tagged wild
type cyclin D1 and HA-tagged T286A cyclin D1. As
shown in Fig. 4a, exogenous wild type cyclin D1 was
decreased by PF, whereas the degradation of T286A
cyclin D1 was suppressed. In addition, we observed
that PF phosphorylated Thr-286 of cyclin D1 (Fig. 4b).
These results suggest that Thr-286 site plays an im-
portant role in PF-induced cyclin D1 degradation.
Fig. 2 The effect on PF on the protein expression of cyclin D1 and CDK4 in human colorectal cancer cells. a-d The cells were treated with the
indicated concentrations of PF for 24 h. e HCT116 cells treated with PF (25 μg/ml) for the indicated times. Cell lysates were subjected to SDS-PAGE
and the Western blot was performed using antibodies against cyclin D1 and CDK4. Actin was used as internal control for Western blot analysis.
*P < 0.05 compared to cell without PF treatment
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Upstream kinases associated PF-mediated degradation of
cyclin D1 and CDK4 protein
To investigate the upstream kinases associated with
PF-mediated degradation of cyclin D1 and CDK4 pro-
tein, HCT116 cells were pretreated with PD98059
(20 μM, inhibitor of extracellular signal–regulated
kinase 1/2 (ERK1/2)), SB203580 (20 μM, p38 inhibi-
tor), SP600125 (20 μM, inhibitor of c-Jun N-terminal
kinases (JNK)) or LiCl (20 mM, inhibitor of glycogen
synthase kinase 3β (GSK3β)) for 2 h, and then co-
treated with PF for 3 h for cyclin D1 or 10 h for
CDK4. As shown in Fig. 5a, cyclin D1 degradation by
PF was attenuated in presence of the ERK1/2 and
GSK3β inhibitor, whereas PF-mediated CDK4 degrad-
ation was blocked in presence of GSK3β inhibitor,
which suggests that cyclin D1 degradation by PF is
dependent on both ERK1/2 and GSK3β, and CDK4
degradation by PF is dependent on GSK3β. Thus, we
examined whether PF induces the phosphorylation of
these kinase as the active form. As shown in Fig. 5b,
the phosphorylation of ERK1/2 and GSK3β was in-
duced at early time points in the presence of PF. In
addition, we observed the inhibition of ERK1/2 and
GSK3β attenuated PF-mediated Thr-286 phosphoryl-
ation of cyclin D1 (Fig. 5c).
Discussion
Psoralea Fructus (PF), the dried and ripe fruit of Psora-
lea corylifolia known as “Bo-Gol-Zhee” in Korea has
been known as an important medicinal plant used in
several traditional medicines to cure various diseases [3].
The extracts of PF have been reported to possess various
pharmacological properties such as antibacterial, anti-
cancer, antioxidant, anti-inflammatory, antifungal and
immunomodulatory activity [3]. In anticancer activity,
PF inhibited hypoxia-inducible factor-1 (HIF-1) activa-
tion in human gastric cancer cells [16]. Administration
of ethanol extract of PF (100 and 200 mg/kg) inhibited
EAC ascitic tumor growth [17]. In addition, PF has been
reported to possess cytotoxic activity against human
stomach carcinoma, colorectal cancer and breast cancer
cells [18, 19] and to induce the cell growth arrest in hu-
man oral carcinoma lines and erythroleukemia cells [5].
Cyclin D1 and CDK4 have been regarded as cell cycle
regulators that control the G1 to S phase of the cell
cycle. These proteins have been considered pivotal target
proteins in various cancers because many anti-cancer
drugs can inhibit the expression of cyclin D1 and CDK4.
Thus, the investigation of the molecular mechanism by
which PF down-regulates cyclin D1 and CDK4 expres-
sion may be required to understand how to better treat
Fig. 3 PF induces the proteasomal degradation of cyclin D1 and CDK4. a-d The cells were treated with the indicated concentrations of PF for
24 h. For RT-PCR analysis of the gene expression of cyclin D1 and CDK4, total RNA was prepared after PF treatment for 24 h. GAPDH was used as
internal control for RP-PCR. e HCT116 cells were pretreated with MG132 for 2 h, and then co-treated with PF (25 μg/ml) for 3 h (cyclin D1) or
10 h (CDK4). Cell lysates were subjected to SDS-PAGE and the Western blot was performed using antibodies against cyclin D1 and CDK4. Actin
was used as internal control for Western blot analysis. *P < 0.05 compared to cell without PF treatment
Park et al. BMC Complementary and Alternative Medicine  (2016) 16:373 Page 5 of 8
cancer and even to develop better anti-cancer drugs. In
this study, we showed that the protein levels of cyclin
D1 and CDK4 is reduced but not mRNA levels in
presence of PF, which indicates that PF may regulate
the protein level of cyclin D1 and CDK4 through
proteasomal-dependent degradation. Cyclin D1 and
CDK4 have been known to be degraded at the translational
level [8, 20]. For cyclin D1 proteasomal degradation, several
modifications such as RXXL motif, T286 and lysine residues
have been identified [8]. HCT116 cells treated PF and
MG132 as the proteasome inhibitor exhibited no degrad-
ation of cyclin D1, and T286A blocked cyclin D1 degrad-
ation by PF. These findings suggest that the downregulation
of cyclin D1 by PF may result from cyclin D1 proteasomal
degradation via T286 phosphorylation. In addition, we ob-
served that PF-mediated decrease of CDK4 protein was
blocked in presence of MG132, showing that PF induces
CDK4 proteasomal degradation. However, we did not deter-
mine how to induce CDK4 proteasomal degradation by PF.
Indeed, C/EBPα has been reported to be involved in CDK4
proteasomal degradation [20]. CCAAT-enhancer-binding
protein α (C/EBPα) overexpression leads to a reduction of
CDK4 protein level, but not mRNA [20]. In addition, C/
EBPα exerts the formation of CDK4-ubiquitin conjugates
and induces CDK4 proteasomal degradation [20]. Thus, the
study for the effect of PF on C/EBPα may be required to
understand the mechanism for the induction of CDK4 pro-
teasomal degradation by PF.
Fig. 4 T286 phosphorylation of cyclin D1 by PF contributes to the proteasomal degradation. a HCT116 cells were transfected with wild type
HA-tagged cyclin D1 or HA-tagged T286A cyclin D1 expression vector, and then treated with PF (25 μg/ml). *P < 0.05 compared to cell without
PF treatment. b HCT116 cells were treated with PF (25 μg/ml) for the indicated times. Cell lysates were subjected to SDS-PAGE and the Western
blot was performed using antibodies against HA-cyclin D1 and p-cyclin D1 (Thr286). Actin was used as internal control for Western blot analysis
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Cyclin D1 degradation dependent on T286 phosphor-
ylation is associated with GSK3β activity [21]. In this
study, GSK3β inhibition by LiCl attenuated PF-induced
cyclin D1 degradation. In addition, we observed that the
inhibition of ERK1/2 blocks cyclin D1 degradation by
PF. Indeed, ERK1/2 has been reported to be involved in
cyclin D1 proteasomal degradation [15, 22]. Although p38
and JNK is involved in cyclin D1 degradation [15, 22], these
two kinases did not affect the downregulation of cyclin D1
by PF. These findings suggest that the upstream kinases in-
volved in PF-mediated cyclin D1 degradation may be
ERK1/2 and GSK3β. Interestingly, we found that the down-
regulation of CDK4 by PF is blocked by GSK3β inhibition
by LiCl, indicating that the upstream kinase involved in PF-
mediated CDK4 degradation may be GSK3β.
Conclusions
This study supports the hypothesis that PF exerts anti-
cancer activity, and downregulation of cyclin D1 and
CDK4 plays a role in PF-induced anti-cancer activity.
Our findings will provide the potential PF usage in the
cancer drug development. Characterization of PF in in
vivo could be required for the further.
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